Why the study?
Does cardiomyocyte-specific sarcoglycan restoration prevent vascular spasm and cardiac degeneration in sarcoglycan-deficient cardiomyopathy?
Does cardiomyocyte-specific sarcoglycan restoration prevent vascular spasm and cardiac degeneration in sarcoglycan-deficient cardiomyopathy?
Cardiomyocyte degeneration, rather than intrinsic vascular smooth muscle defects, drives coronary vascular spasm in sarcoglycan-deficient cardiomyopathy, a process partially mediated by nitric oxide.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for cardiomyocyte-targeted therapy in sarcoglycanopathies; leaves open translation to human disease and clinical use.
Wheeler et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: